A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity.
Drospirenone is a new progestogen in hormone replacement therapy, with anti-mineralocorticoid activity. This anti-mineralocorticoid activity counteracts water and sodium retention, helping to reduce the likelihood of fluid retention that some women experience with hormone replacement therapy. In a post hoc analysis of women with mild hypertension, estradiol (1 mg) plus drospirenone (2 mg) was found to lower blood pressure in mildly hypertensive women. The introduction of estradiol plus drospirenone may offer the opportunity to re-evaluate the contribution of the progestogen component of hormone replacement therapy.
Stevenson
John C
JC
National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK. j.stevenson@imperial.ac.uk
D000368:Aged; D000736:Androstenes / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination; D004487:Edema / Q000517:prevention & control; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D008593:Menopause / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D008901:Mineralocorticoids / Q000037:antagonists & inhibitors; D011372:Progestins / Q000008:administration & dosage*; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D006113:United Kingdom
D000736:Androstenes; D008901:Mineralocorticoids; D011372:Progestins; C035144:drospirenone